Systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for sarcopenia.
Kang-Fu YinTing ChenXiao-Jing GuWei-Ming SuZheng JiangSi-Jia LuBei CaoLi-Yi ChiXia GaoYong-Ping ChenPublished in: Journal of cachexia, sarcopenia and muscle (2024)
Our research indicated MAP 3K3, MFGE8, COL15A1, HP, and HLA-DRA may serve as promising targets for sarcopenia, while the effectiveness of zinc supplementation and collagenase clostridium histolyticum for sarcopenia requires further validation.